Evotec AG Announces NMDA Antagonist License Agreement
HAMBURG, Germany, Dec. 17, 2012 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) today announced that it has entered into a license agreement with Janssen Pharmaceuticals, Inc. ("Janssen") regarding its NR2B subtype selective NMDA-antagonist portfolio for development against diseases in the field of depression.